USE OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICINE FOR TREATING NON-HODGKIN' S LYMPHOMAS

摘要

Disclosed is the use of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) for the manufacture of a medicament for the treatment of CD20 expressing cancer in combination with one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine, wherein said type II anti-CD20 antibody is a glycoengineered, humanized B-Ly1 antibody, and the treatment with the type II anti-CD antibody is in combination (a) with cyclophosphamide and vincristine, or (b) with doxorubicine, or (c) with cyclophosphamide, or (d) with cyclophosphamide, vincristine and doxorubicine